Kornimate/medical-research-clean huggingface dataset:
post-covid-19 outpatient care and biomarkers

Conditions: Post Viral Fatigue; Viral Myocarditis; POTS

Summary: the aims of this case-control, non-randomized study including patients with post-covid-19 persisting symptoms are 1) to establish the large blood biobank, 2) to examine levels of circulating inflammatory biomarkers and different classes of non-coding rnas (ncrna), such as selected circrnas and mirnas, in plasma and serum samples collected from patients with post- covid-19, 3) to test the levels of cfdna in plasma and serum, 4) to define correlation between ncrnas and cf-dna with persistent clinical symptoms, and type of symptoms, and 5) to investigate diagnostic and prognostic performances of these circulating biomarkers. study design. this is a prospective registry including biobank.

currently, several studies are ongoing to investigate different treatment modalities of post-covid-19 symptoms, but there is a complete lack of investigations on biomarkers predicting type, duration or severity of post-covid-19 symptoms. the aim of this study is to investigate circulatory biomarkers diagnostic or predictive for long/post-covid-19 syndrome. study patients. patients with at least 3 weeks after proven infection by sars-cov-2, reflected by at least one positive pcr-test in nose throat swabs, who visits at the post-covid-19 outpatient clinic of the medical university of vienna, will be consequently recruited into the presented registry. additionally, 100 vaccinated patients with hfref and 100 healthy vaccinated volunteers will be recruited to serve as comparison groups. methods. identity of the registry patients will be protected by pseudonymization. during the ambulatory visit, basic clinical examination, electrocardiogram, chest x-ray, routine laboratory tests will be performed. additionally, venous blood will be collected for biobank. expected outcome this registry will provide further insights regarding pathophysiology, risk stratification and treatment of complex post-covid-19 symptoms. specific therapies and search of prognostic factors will enable to select patients with high risk of persistence or worsening of their symptoms thereby improve patient care.

Eligibility criteria:
inclusion criteria: for post-covid patient group: * age≥18to90years * proven infection by sars-cov2, at least 3 weeks after recovery from the infection * signed informed consent for hfref patient group: for vaccinated healthy volunteer control group: * full vaccination against sars-cov2 at least 3 weeks before inclusion in the study * signed informed consent exclusion criteria: * non-willingness to participate or withdrawal of informed consent * clinically confirmed hfref (ef \<40%) * participation in any sars-cov-2 medical treatment trial * pregnancy

Keywords: long/post-covid multiorgan disease biomarkers cardiovascular imaging
the effect of direct cyclophotocoagulation using endolaser in silicon induced glaucoma: a pilot study.

Conditions: Glaucoma

Summary: transcleral cyclophotocoagulation has been used to treat glaucoma secondary to silicone oil


Eligibility criteria:
inclusion criteria: . patients above 18 years of age. .silicon filled for more than 2 months. .iop more than 21 mmhg on triple topical antiglaucoma eye drops. exclusion criteria: . history of glaucoma prior to the initial retinal surgery. . immediate rise of iop after soi. . history of previous laser application to the ciliary body. . any contraindications for silicone oil removal.
parents' experience of their children stay in a pediatric intensive care unit.

Conditions: Intensive Care Unit Syndrome

Summary: children recovered in pediatric intensive care unit (picu) suffer from severe conditions, sometimes life-threatening. thus, priority is given to urgent somatic care, children medicalization is strong, invasive technics have to be used, and medical monitoring is close. a stay in picu often leaves a painful memory to the child and family, and can lead to psychological morbidity such as post-traumatic stress disease. this study aims to assess parents' experience during their child hospitalization in picu, and the impact of this stay on the entire family in the following month.


Eligibility criteria:
inclusion criteria: * parent (mother or /and father) of a recovered child in picu. * no limit of age, disease or admission mode. * first stay in picu, for at least a 3 days stay. * parents having been informed and having accepted the participation in the study. exclusion criteria: * death of the child during the stay in picu or during the month following the discharge from picu * non-fluent french speakers/readers.
outcomes of neonates born to mothers with sars-cov-2 infection in shanghai

Conditions: SARS-CoV2 Infection; Neonatal Infection; Outcomes

Summary: since march 2022, there are an outbreak of sars-cov-2 infection (omicron) in shanghai. this cohort study aims to analysis the clinical outcomes of neonates born to mothers with sars-cov-2 infection.


Eligibility criteria:
inclusion criteria: * neonates born to mothers with sars-cov-2 infections. exclusion criteria: * parents who rejected to participate in this study.
a retrospective validation study to identify chart-based clinical diagnosis of wild-type transthyretin amyloid cardiomyopathy (attrwt-cm) and non-amyloid heart failure among patients with heart failure (hf).

Conditions: ATTR-CM

Summary: this is an observational, retrospective non-inferiority study with a study sample from a large national database. a machine learning (ml) model will use a national database to predict the clinical diagnosis of attrwt-cm among hf patients. this study will include hf patients ≥50 years old.


Eligibility criteria:
inclusion criteria: * hf patients (defined as having ≥1 claim for hf or hf treatment) ≥50 years old with clinical diagnosis of attrwt-cm or non-amyloid hf ascertained by charts. patients will be required to have ≥12 months of continuous activity in the ehr or claims prior to the index date. exclusion criteria: * patients with any of the following diagnoses: * light chain (al) amyloidosis * intracranial hemorrhage * cerebral amyloid angiopathy * end stage renal disease * blood cancer

Keywords: chronic heart failure
use of prophylactic steroids in the prevention of post-thyroidectomy hypocalcaemia and voice dysfunction

Conditions: Thyroid Diseases; Hypocalcemia; Vocal Cord Dysfunction

Summary: total thyroidectomy for benign surgical pathologies is associated with risks related to temporary hypocalcaemia and vocal quality dysfunction. dexamethasone, as an anti-inflammatory steroid, has been proposed to have a physiological effect on hypocalcaemia and voice quality. investigators conducted a double-blinded controlled trial to assess the effect of preoperative dexamethasone on the vocal dysfunction and hypocalcaemia following thyroidectomy


Eligibility criteria:
inclusion criteria: * benign thyroid condition. * patients without any preoperative corrected hypocalcaemia and voice or vocal quality dysfunction. exclusion criteria: * previous thyroid or neck surgery * known vocal cord dysfunction on laryngoscopy * hearing or voice problems * history of gastroesophageal reflux and stomach ulcer disease * contraindications of steroids

Keywords: thyroidectomy postoperative hypocalcaemia postoperative vocal cord dysfunction dexamethasone
tes effects on associative memory performance

Conditions: Healthy; Mild Cognitive Impairment; Alzheimer Disease

Summary: previous studies showed that transcranial electric stimulation (tes) applied over the prefrontal cortex improves cognitive performance in healthy elderly adults as well as in patients suffering from mild cognitive impairment or early alzheimer's disease. therefore, tes methods might be a useful intervention tool for patients suffering from memory impairment in early terms of the disease. the present study aims at establishing a connection between the stimulation-induced changes on associative memory performance and its underlying neurophysiological parameters. tes effects and their underlying mechanisms will be compared between healthy elderly controls and clinical study populations receiving either real or sham tes over the left ventrolateral prefrontal cortex during an associative memory task.


Eligibility criteria:
inclusion criteria: * written informed consent * non-smokers * right-handedness * native german speakers or comparable level of fluency * normal or corrected-to-normal vision exclusion criteria: * neurological or psychiatric condition (other than diagnosed cognitive impairment) * past head injuries * magnetizable implants * history of seizures * current or life-time alcohol or drug abuse * skin diseases
non interventional study in patients with open angle glaucoma and/or ocular hypertension treated with xalatan®

Conditions: Glaucoma,Open-Angle; Ocular Hypertension

Summary: the primary objective is to evaluate the intraocular pressure reducing effect of xalatan over 3 months. the secondary objective is to study the other efficacy parameters during treatment for 3 months


Eligibility criteria:
inclusion criteria: * unilateral or bilateral open angle glaucoma or ocular hypertension (iop (intraocular pressure) ≥ 21 mmhg at diagnosis). * naive patients (no prior anti-glaucoma pharmacological or surgical treatment) and patients with beta-blockers therapy failure * visual acuity (best corrected) equal to or better than 6/6 exclusion criteria: * closed/barely open anterior chamber angle or history of acute angle closure glaucoma. * history of any antiglaucoma surgical treatment (argon laser trabeculoplasty and/or any ocular filtering surgical intervention). * ocular surgery (on the globe of the eye only), or inflammation/infection within 3 months prior to baseline visit. (applies to both fellow and study eyes.) * other abnormal ocular conditions or symptoms preventing the patient from entering the study, in the investigator's clinical judgement.
vaccine therapy in treating patients with chronic myelogenous leukemia

Conditions: Leukemia

Summary: rationale: vaccines may make the body build an immune response to kill cancer cells. purpose: phase ii trial to study the effectiveness of vaccine therapy in treating patients who have chronic myelogenous leukemia.

objectives: * determine the safety and immunogenicity of a multivalent tumor-specific breakpoint peptide vaccine in patients with chronic myelogenous leukemia. * determine the antileukemic effects of vaccination with these peptides in these patients. outline: patients receive bcr/abl breakpoint peptide vaccine in qs21 adjuvant subcutaneously at rotated sites every 1-3 weeks (on or about days 0, 7, 21, 35, and 56) over 8 weeks. treatment continues in the absence of disease progression or unacceptable toxicity. patients demonstrating a response by week 10 may receive 3 additional monthly vaccinations initiated within 8 weeks of the fifth dose. patients demonstrating a response by vaccination 8 may receive 3 additional vaccinations administered at two-month intervals. patients are followed at 2 weeks. projected accrual: a total of 24 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * histologically proven chronic myelogenous leukemia * must have (9;22) translocation or bcr/abl transcript, and b3a2 breakpoint * no accelerated or blastic phase * must be in hematologic remission with peripheral wbc less than 20,000/mm\^3 patient characteristics: age: * over 16 performance status: * karnofsky 70-100% life expectancy: * not specified hematopoietic: * see disease characteristics * absolute granulocyte count greater than 1,200/mm\^3 * platelet count greater than 70,000/mm\^3 * hemoglobin greater than 9.0 g/dl * no active bleeding hepatic: * bilirubin less than 2.0 mg/dl * lactate dehydrogenase less than 2 times normal renal: * creatinine less than 2.0 mg/dl cardiovascular: * no new york heart association class iii or iv heart disease other: * no uncontrolled active infection requiring antibiotics * no other serious illness * no immunodeficiency other than from prior bone marrow transplantation * not pregnant or nursing prior concurrent therapy: biologic therapy: * at least 6 months since prior allogeneic or autologous bone marrow transplantation * prior vaccination with pentavalent peptide at less than study dose level allowed * at least 4 weeks since prior immunotherapy other than interferon, donor lymphocyte infusion, or pentavalent vaccine * concurrent interferon allowed chemotherapy: * at least 2 weeks since prior low-dose subcutaneous cytarabine * at least 4 weeks since prior chemotherapy other than hydroxyurea * no concurrent chemotherapy except hydroxyurea endocrine therapy: * no concurrent corticosteroids radiotherapy: * at least 4 weeks since prior radiotherapy * no concurrent radiotherapy surgery: * no concurrent surgery other: * concurrent imatinib mesylate allowed * no other concurrent systemic therapy

Keywords: relapsing chronic myelogenous leukemia chronic phase chronic myelogenous leukemia
comparison of current subgingival debridement methods

Conditions: Treatment of Periodontitis; Guided Biofilm Therapy; Subgingival Plaque; Subgingival Debridement

Summary: our study aimed to compare the effectiveness of current subgingival debridement methods used in the treatment of stage 1 and stage 2 periodontitis patients, the aesthetic condition achieved after these treatments, and the pain felt during treatment. 90 female patients who were diagnosed with chronic periodontitis (stage 1-2) and required supra-subgingival scaling for treatment purposes, and who volunteered to participate in the study, were included in the study. three treatment groups were determined. 30 people were included in each group. periodontal examination was performed before and after the treatments in the 1st month, 3rd month and 6th month and the data on the collected periodontal parameters were analyzed.

periodontal parametreler gingival index, plaque index, periodontal pocket depth and bleeding index on probing. it was evaluated with the visual analog scale for pain and aesthetics.

Eligibility criteria:
inclusion criteria: * systemically healthy patient (without known chronic disease) * periodontal diagnostic data (gingival index, plaque index, periodontal pocket depths, attachment loss, radiological data-bone loss data) are complete * treatments diagnosed with stage 1-2 periodontitis and those who have not had periodontal treatment in the last 6 months exclusion criteria: * having a systemic disease * pregnant and lactating women * smoker * those who do not want to participate in the study

Keywords: guided biofilm therapy periodontitis subgingival debridement
optimal dosing of ic-green for visualization of rotator cuff vascularity using advanced imaging modality arthroscopy

Conditions: Rotator Cuff Tears

Summary: rotator cuff re-tear is a common delayed complication of arthroscopic rotator cuff repair. this process of re-tear is multifactorial and there has not been any readily identifiable perioperative measure that is predictive of subsequent rotator cuff failure. there have been no human studies looking at intraoperative assessment of rotator cuff vascularity, nor the predictive value that vascularity may have for rotator cuff re-tear. indocyanine green (icg) has been safely used in patients for visualization purposes and has real potential for identifying vascularity in arthroscopic surgical patients. the aim of this study is to establish a standard dosing protocol for icg in the arthroscopic visualization of rotator cuff vascularity.

the primary study objective is to determine optimal dosing of an intravenous fluorescence solution (ic-green) for arthroscopic evaluation of rotator cuff vascularity. the primary endpoint is surgeon's ability to assess vascularity within the rotator cuff based on a 5-point likert scale. the likert values from each of the three doses will undergo an anova test to compare means of the three doses.

Eligibility criteria:
inclusion criteria: * patients has full or partial thickness rotator cuff tear and is scheduled to undergo arthroscopic rotator cuff repair * patient is at least 18 years of age and less than 80 years of age exclusion criteria: * patient is less than 18 years of age or greater than 79 years of age * patient has a documented allergy to iodides * patients who have had iodide based radiology studies within the last seven (7) days prior to surgery * patient is pregnant
descriptive pilot study of the effects of a standardized neuromodulation program on cortical brain function in chronic low back pain patients

Conditions: Low Back Pain; Chronic Low Back Pain

Summary: this study aims to evaluate neurofeedback-induced changes in brain function and the correlations between these changes and clinical scores by functional magnetic resonance imaging and electroencephalography in patients with low back pain.


Eligibility criteria:
inclusion criteria: * patient with a wifi connexion at home * patient with the ability to modulate the height of the candle by thinking in the alpha synchrony test. * patient with chronic low back pain for more than six months with a visual analogue pain scale greater than 5 impacting activities of daily living, hobbies and work * patient having given free and informed consent and signed consent. * affected patient or beneficiary of a health insurance plan. * patient who is at least 18 years old (≥) and younger than 75 years old (\<). exclusion criteria: * pregnant or breastfeeding patient * patient with a contraindication to performing a fmri scan: ferromagnetic implant in the body, piercing, claustrophobia, unable to remain in the scanner stationary for 40 minutes * patient already included in another study * patient in a exclusion period determined by a previous study * the subject is under the protection of justice, guardianship or curatorship. * the subject refuses to sign the consent. * it is not possible to give the subject informed information.
a study to investigate the pharmacokinetic/pharmacodynamic characteristics of ibi128(a new xanthine oxidase inhibitor)

Conditions: Gout Arthritis

Summary: a phase i study to evaluate the pharmacokinetic/pharmacodynamic characteristics,safety and tolerability of ibi128 after multidosing in chinese health subjects.


Eligibility criteria:
inclusion criteria: 1. healthy male subjects between the ages of 18 and 50 years at screening; 2. subjects with a body mass index (bmi) between 18.0 (inclusive) and 28.0 kg/m2 (inclusive); and a total body weight ≥55kg (male） and 45kg (female) 3. participants who are overtly healthy as determined by medical evaluation including medical history, laboratory tests, vital signs and standard 12 lead ecgs. 4. subject is willing to participate and to sign written informed consent form. exclusion criteria: 1. subjects with a history of hypersensitivities to investigational products, including drug allergies (caused by aspirin, antibiotics, etc.), or a history of clinically significant hypersensitivities 2. subjects with evidence or a history of gastrointestinal disease (crohn's disease, ulcer, acute or chronic pancreatitis, etc.) or surgery (except simple appendectomy or repair of hernia) that may influence drug absorption 3. subjects with evidence or a history of clinically significant hepatic (including carrier of viral hepatitis), renal, neurologic, immunologic, pulmonary, endocrine, hematological, neoplastic, cardiovascular or psychiatric (mood disorder, obsessive-compulsive disorder, etc.) diseases. 4. subjects with a history or current have mental disease. 5. subjects who have taken any medicine that may affect outcomes within 30 days before the first administration of the investigational product. 6. subject who have taken ibi128 in other studies. 7. subjects who have a history of acute arthiritis. 8. pregnant women or breast-feeding women or men and women who has possibility of pregnancy. 9. subjects judged not eligible for the study after reviewing the clinical laboratory results or other reasons by the investigator
performance of a hearing aid platform including different styles of hearing aids

Conditions: Hearing Loss, Bilateral or Unilateral

Summary: the reason for this study is to evaluate a new hearing aid product generation replacing the one on the market. the goal is to evaluate the audiological performance, usability as well as features and functions.

this is a controlled, single blinded comparative study which is conducted monocentric at phonak headquarters in staefa. the focus is to compare a new hearing aid product generation with the one on the market as well as with competitor devices regarding the audiological performance, usability as well as features and functions with the aid of 382 mild to profound hearing impaired subjects (18-90 yrs). the subjects, all of them native (swiss) german speakers, individually conduct a number of laboratory standard tests and home trials (questionnaires) during nine weeks including weekly appointments of 2 hours.

Eligibility criteria:
inclusion criteria: * all kinds of hearing loss (sensorineural, conductive, combined) * all kinds of hearing loss (flat, sloping) which are in the fitting range of the hearing aids * mother tongue (swiss) german exclusion criteria: subjects * with a reduced mobility unable to attend weekly study appointments * without access to a number of different hearing situations * with strongly reduced ability to describe auditory impressions and the usage of the hearing aids * which are uncooperative so that it is not possible to record a valid pure tone audiogram * with a strongly reduced dexterity * with psychological problems * central hearing disorders
stereotactic mri based image guidance for the treatment of vascular malformations - a pilot study

Conditions: Vascular Malformations

Summary: treatment of vascular malformations requires the placement of a needle within anatomically non well defined, pathological vessels, which may be as small as 1 mm, with the current state of the art relying exclusively on two dimensional fluoroscopy images for guidance. the investigators hypothesize that the combination of stereotactic image guidance with existing targeting methods will result in faster and more reproducible needle placements.

this prospective study aims to investigate the feasibility of the utilization of stereotactic image guidance technology for the needle based percutaneous treatment of peripheral vascular malformations. the specific device to be utilized is the cas-one ir system, ce marked for use with needle based procedures in combination with medical image data including mri data, as required by this study. utilizing feedback from the stereotactic image guidance system, the interventionalist will attempt to place the needle within the malformation. the position and orientation of the needle relative to the anatomy will be displayed on 2d slices from the mri, as well as relative to a 3d volume rendering of the patient anatomy constructed from mri data. the position of the needle relative to the desired position within the malformation will be evaluated utilizing fluoroscopy. if necessary the position of the needle will be adjusted, this adjustment can be performed utilizing navigated feedback or standard fluoroscopy feedback at the discretion of the physician. the final position of the needle will be confirmed on intra-operative dsa imaging and the sclerosant will be applied according to standard clinical protocols. this single-centre pilot study will involve a total of 10 patients suffering from peripheral vascular malformations. only non-emergency adult patients will be considered for inclusion in this trial. inclusion will be at the discretion of the treating physician and patient. as the study is designed as a pilot trial, no comparator is considered and no blinding performed. the trial will be performed over a period of nine months.

Eligibility criteria:
inclusion criteria: * patients with venous or mixed venous-lymphatic malformation * patients which are regular scheduled for a percutaneous treatment of a vascular malformation * informed consent as documented by signature exclusion criteria: * age \< 18 years

Keywords: vascular malformations image guidance